Moleculin closes Part A enrollment in MIRACLE AML trial at 89, one subject still in screeningSep 29Trial updateMoleculin Biotech, Inc.
Roswell Park's Phase II CPX-351 trial in younger secondary AML patients marked completedAug 31Trial updateJazz Pharmaceuticals
Moleculin reports positive interim MIRACLE data, keeps trial timeline on trackAug 14Quarterly updateMoleculin Biotech, Inc.
Vanderbilt registers Phase 2 Lazarus trial testing IT therapy to prevent ICANS after CAR TAug 13Trial updateGilead Sciences
Moleculin reports 37% blinded CRc in venetoclax-failed AML patients from MIRACLE trialJul 31Clinical readoutMoleculin Biotech, Inc.venetoclax
Sign inSign in